CurrentCareSourcePolicy N/A

Alpha-1 Proteinase Inhibitor (AAT) Products — Medical Benefit Coverage Criteria

Defines medical benefit prior authorization, coverage criteria, and dosing for intravenous alpha-1 antitrypsin (AAT) augmentation therapy (e.g., Aralast, Glassia, Prolastin-C, Zemaira) for members; applies to medical providers seeking coverage for these products.

Policy Summary

PayerCareSource

PolicyAlpha-1 Proteinase Inhibitor (AAT) Products — Medical Benefit Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateDec 11, 2024

Key ActionObtain prior authorization and document serum AAT level below the protective threshold (≈11 mcM / ~80 mg/dL) and patient age/status to support approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

60 mg/kgrecommended weekly dose for approved indications

1 yearstandard approval duration

11 mcMprotective threshold cited

≥18age requirement

Coverage and Medical Necessity Criteria

Policy Summary

PayerCareSource

PolicyAlpha-1 Proteinase Inhibitor (AAT) Products — Medical Benefit Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateDec 11, 2024

Key ActionObtain prior authorization and document serum AAT level below the protective threshold (≈11 mcM / ~80 mg/dL) and patient age/status to support approval.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Alpha-1 proteinase inhibitor therapy is not recommended for individuals with AAT deficiency without lung disease, including cases with AAT-related hepatic disease. The policy cites lack of evidence of benefit for liver disease and notes that liver pathophysiology differs from pulmonary disease, so augmentation is not indicated in these patients.

Therapy is also not recommended for patients with bronchiectasis without AAT-related emphysema; available studies suggest bronchiectasis in these patients is more commonly secondary to parenchymal emphysematous changes than a direct consequence of AAT deficiency.

Coverage is not recommended for other circumstances not listed in the Recommended Authorization Criteria; criteria will be updated if new published data become available.

Alpha-1 proteinase inhibitor augmentation therapy is not medically necessary for treatment of COPD that is not related to documented alpha-1 antitrypsin deficiency. The policy references guideline conclusions that augmentation is intended for AAT-deficiency–related emphysema and is not recommended for routine COPD care when AAT deficiency has not been demonstrated.

Requests for augmentation therapy for COPD without documented AAT deficiency are therefore likely to be denied under this policy.

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for medical benefit coverage of alpha-1 proteinase inhibitor products. Approval is recommended only for members who meet the policy's specified criteria and dosing. All approvals are provided for the duration noted in the policy. Requests for doses outside the established dosing will be reviewed case-by-case by a clinician (Medical Director or Pharmacist).

Prior authorization required for alphag-/alpha-1 proteinase inhibitor products
Requests for non-standard dosing reviewed case-by-case
Approvals provided for specified duration when criteria met

Step Therapy

Step Therapy / Automation

No automated step therapy requirements are specified for alpha-1 proteinase inhibitor therapy. There is no programmatic automation; dose exceptions and requests outside the standard dosing regimen will be considered on a case-by-case basis.

Automation: None
No step therapy or automated fail-first requirements specified
Dose exceptions considered case-by-case by clinical reviewer

Documentation Required

Required Clinical Documentation

Clinical documentation must support the diagnosis of alpha-1 antitrypsin (AAT) deficiency and the medical necessity for augmentation therapy. Documentation should include quantitative serum AAT level with method of measurement (nephelometry or radial immunodiffusion) and supporting clinical information.

Quantitative serum AAT level required (report value and assay method)
If measured by nephelometry: level consistent with deficiency (e.g., < 57 mg/dL equivalent)
If measured by radial immunodiffusion: note that values correspond differently (e.g., < 80 mg/dL corresponds to ~11 mcM)
Supporting clinical information (age, smoking status, presence of emphysema/COPD) and prescriber rationale

Denial Risk

Situations Likely to Be Denied

Requests are likely to be denied when documentation does not demonstrate AAT deficiency, when AAT therapy is requested for non-covered indications, or when clinical criteria in the policy are not met.

Requests without documented AAT deficiency (no quantitative AAT level or level above deficiency thresholds)
Requests for augmentation therapy for liver disease alone or for COPD without documented AAT deficiency
Requests that do not include required clinical documentation (assay method, smoking status, evidence of emphysema) or that fall outside the policy's recommended indications

Background and Rationale

Alpha-1 antitrypsin (AAT) deficiency is an autosomal co-dominant hereditary disorder characterized by low plasma concentrations of AAT that can lead to progressive emphysema, typically appearing in mid-adulthood. Diagnosis begins with a quantitative plasma AAT measurement; a level at or below the policy's protective threshold (11 micromol/L, approximately the tenth percentile for some genotypes) suggests deficiency.

Intravenous AAT augmentation therapy is intended to raise serum AAT toward the theoretical protective threshold to slow emphysema progression. Evidence and guideline statements support use primarily in patients with documented AAT deficiency and emphysema (or AAT-related COPD), particularly in non-smokers or ex-smokers; the policy notes limited evidence for use in other manifestations such as bronchiectasis or liver disease, and therefore restricts coverage to specified indications.

Definitions and Protective Threshold

Protective threshold — definition and equivalents

Protective thresholdSerum AAT level of 11 micromol/L (11 mcM) — target level used as the theoretical protective threshold

Equivalent (radial immunodiffusion)Approximately 80 mg/dL by radial immunodiffusion (older assay that overestimates concentration)

Equivalent (nephelometry)Approximately <57 mg/dL by nephelometry (commonly used modern assay)

Clinical relevanceThreshold represents ~10th percentile of PI*SZ individuals and is used as the treatment target to reduce risk of emphysema progression

OpenPayer

Alpha-1 Proteinase Inhibitor (AAT) Products — Medical Benefit Coverage Criteria

Coverage and Medical Necessity Criteria

Key Numeric Thresholds and Coding Definitions

Prior Authorization, Documentation, and Denial Risks

Background and Rationale

Definitions and Protective Threshold